Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026
Same author

Local Consolidative Radiotherapy Combined With Immunochemotherapy for De Novo Metastatic Nasopharyngeal Carcinoma: A Meta-Analysis.

Head & neck·2026
Same author

Immunotherapy plus induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemotherapy with cisplatin vs induction chemotherapy followed by two cycles of concurrent chemotherapy with cisplatin in locoregionally advanced nasopharyngeal carcinoma.

Frontiers in immunology·2026
Same author

Efficacy and safety of hypofractionated radiotherapy combined with temozolomide in patients with newly diagnosed glioblastoma with poor prognosis: a single-center retrospective analysis.

Frontiers in oncology·2026
Same author

Reply to "Design-analysis mismatch in the analysis of longitudinal HER2 data in breast cancer".

Cancer·2026
Same author

Perineural invasion and risk of lymph node metastasis in early-stage operable breast cancer: a large-scale propensity-matched cohort study and meta-analysis.

Therapeutic advances in medical oncology·2026

Related Experiment Video

Updated: Jun 24, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Bionic Copper-Piceatannol for Polyamine Depletion-Synergized Radioimmunotherapy.

Teng Zou1, Hongwei Wang2, Fangmeng Fu1

  • 1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China.

ACS Applied Materials & Interfaces
|June 23, 2026
PubMed
Summary

This study introduces a novel nanoplatform that combats radiotherapy resistance by reducing hypoxia, depleting polyamines, and boosting antitumor immunity. This approach enhances radiotherapy efficacy and significantly lowers tumor recurrence rates.

Keywords:
immunogenic cell deathmetal polyphenolplatelet membraneradioimmunotherapytumor recurrence

More Related Videos

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
06:52

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
11:04

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Published on: September 7, 2019

Related Experiment Videos

Last Updated: Jun 24, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
06:52

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
11:04

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Published on: September 7, 2019

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Research

Background:

  • Radiotherapy (RT) efficacy is limited by factors like tumor hypoxia, high glutathione levels, and immunosuppressive tumor microenvironments (ITME).
  • Overcoming these challenges requires multifaceted strategies to enhance RT-induced tumor damage and immune response.

Purpose of the Study:

  • To develop a novel nanoplatform (PCuP) that addresses multiple RT resistance mechanisms simultaneously.
  • To evaluate the efficacy of PCuP in combination with RT for treating oral squamous cell carcinoma (OSCC) and preventing tumor recurrence.

Main Methods:

  • Fabrication of a biomimetic nanoplatform (PCuP) using copper ions, piceatannol, and platelet membranes.
  • In vitro and in vivo evaluation of PCuP's ability to relieve tumor hypoxia, induce immunogenic cell death (ICD), deplete polyamines, and inhibit arginase 2 (Arg2).
  • Assessment of PCuP-mediated immune activation, including dendritic cell maturation and systemic antitumor immunity in OSCC models.

Main Results:

  • PCuP demonstrated preferential accumulation in tumor tissues.
  • PCuP effectively relieved intratumoral hypoxia by catalyzing hydrogen peroxide to oxygen.
  • The nanoplatform generated reactive oxygen species (ROS) to enhance RT-induced ICD and inhibited arginase 2 (Arg2) to deplete polyamines, thereby suppressing tumor DNA repair.
  • PCuP promoted dendritic cell maturation and activated systemic antitumor immunity, leading to a significant reduction in post-RT tumor recurrence in OSCC models.

Conclusions:

  • The developed PCuP nanoplatform represents a novel strategy for radioimmunotherapy by integrating polyamine depletion with RT.
  • This approach shows significant promise for overcoming RT resistance, enhancing antitumor immunity, and reducing tumor recurrence in OSCC.
  • PCuP offers a potential new avenue for designing advanced radiosensitizers to improve clinical RT outcomes.